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Case Report
Encapsulating pEritonEal sclErosis 
prEsEnting With haEmorrhagic ascitEs 
aftEr transfEr from pEritonEal Dialysis 
to haEmoDialysis
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Division of  Nephrology, Department of  Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
abstract
A patient with end-stage kidney disease due to chronic glomerulonephritis was initiated on continuous ambulatory 
peritoneal dialysis. After three years he was transferred to haemodialysis following recurrent episodes of  peritonitis. 
After the commencement of  haemodialysis the patient developed progressive abdominal distension; paracentesis 
revealed bloody ascites. Radiographic imaging revealed features of  small bowel obstruction with bowel loops matted to 
the posterior abdominal wall. A diagnosis of  encapsulating peritoneal sclerosis was made. Treatment with prednisone 
was initiated but the patient’s condition steadily worsened and he demised a year later due to severe malnutrition and 
sepsis.
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bacKgrounD 
Encapsulating peritoneal sclerosis (EPS) is a rare but 
devastating complication of  peritoneal dialysis. A recent 
study reported an incidence rate of  1.8/1000 patient-
years [12]. It usually presents insidiously with non-specific 
abdominal symptoms and has a very poor prognosis, 
with most cases proving resistant to therapy. The disease 
progresses relentlessly until death occurs from malnutrition 
and sepsis. We report a case of  EPS presenting with bloody 
ascites.
casE
A 40-year-old male with end-stage kidney disease 
secondary to chronic glomerulonephritis was commenced 
on continuous ambulatory peritoneal dialysis (CAPD) 
in December 2005. He did not have hypertension. His 
peritoneal dialysis prescription consisted of  five exchanges 
daily (4 x 2L of  2.3% dextrose and 1 x 2L of  4.25% dextrose 
solution). 
In 2006 he had two episodes of  peritonitis secondary to 
Staphylococcus epidermidis, each episode being successfully 
treated with vancomycin. However, in February 2009, he 
developed non-resolving peritonitis, the Tenckoff  catheter 
was removed, and he was transferred to haemodialysis.
At the end of  May 2009 he presented with weight loss, poor 
appetite and vague abdominal symptoms and was found to 
have abdominal distension with shifting dullness. CRP was 
raised at 135mg/L. Abdominal radiograph revealed multiple 
air fluid levels (Figure 1, panel A) and an ultrasound revealed 
a large volume of  free intra-abdominal fluid. A paracentesis 
revealed that the ascitic fluid was bloody. In view of  his 
previous history of  tuberculous (TB) pericarditis, multiple 
samples of  fluid were sent for TB culture. These were all 
negative. Cytological examination of  the ascitic fluid did not 
reveal any malignant cells. 
By June 2009, his symptoms had progressed. His CRP 
remained elevated at 128mg/L. An abdominal computed 
tomography (CT) scan revealed loculated ascites anteriorly 
with the bowels matted to the posterior abdominal wall 
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(Figure 1, panel B). A diagnosis of  encapsulating peritoneal 
sclerosis was made and he was given a therapeutic trial of  
oral prednisone 40mg daily for six weeks. This was stopped 
after he failed to show any clinical response. He had 
progressive deterioration with wasting and malnutrition. In 
July 2010 he developed overwhelming Pseudomonas and 
Klebsiella sepsis which resulted in his demise. 
Discussion
EPS often has a multi-factorial aetiology [2] and our patient 
demonstrated several of  these. 
Our patient was relatively young, a risk factor in some 
studies [10], and had recurrent and non-resolving peritonitis. 
Peritonitis has been regarded as a risk for the future 
development of  EPS [2]; however, some recent evidence 
suggests that peritonitis may not be a risk factor [10]. The 
duration on CAPD is the most important risk factor for 
the development of  EPS [5]. The respective cumulative 
incidences in a recent study at three, five and eight years 
were 0.3%, 0.8% and 3.9% [10]. Our patient’s duration on 
CAPD was only 38 months.
This case demonstrated two of  the key features of  EPS: 
symptoms of  partial bowel obstruction, and typical 
radiologic findings. The diagnosis can usually be made on the 
basis of  the clinical and radiologic evidence [2]. However, a 
definitive diagnosis may require histological evidence [2, 5]. 
We felt that a peritoneal biopsy was not needed due to the 
clear clinical and radiographic evidence.
Symptoms usually have an insidious onset, as in our patient, 
and are due to thickening of  the peritoneum with resultant 
intestinal obstruction [5]. Ultrafiltration failure is common 
and often develops well before a diagnosis of  EPS is made 
[11]. At our centre, we routinely initiate our patients with a 
peritoneal dialysis prescription of  four daily exchanges of  
1.5% dialysate. Our patient required five daily exchanges 
including one 4.5% dialysate exchange. 
Evidence of  bowel obstruction can be obtained using 
radiographic techniques [5]. Our patient had an abdominal 
X-ray picture in keeping with bowel obstruction; however, 
this is not sufficient to make a diagnosis of  EPS. An 
ultrasound of  the abdomen only revealed free fluid. 
Ultrasound may demonstrate the so called “sandwich” 
appearance of  the peritoneal membrane, trilaminar 
thickening of  the membrane, tethering to the posterior 
abdominal wall and dilated, fixed and matted bowel loops 
[6]. CT of  the abdomen revealed several of  these features 
including loculated ascites, tethering of  the bowels to the 
posterior abdominal wall and dilated bowel loops [5, 6]. 
trEatmEnt anD prognosis
The only prospective, multicenter study [2] compared total 
parenteral nutrition (TPN), corticosteroids (in combination 
with TPN alone or TPN plus surgery) and surgery (with 
all receiving TPN). Recovery was 0%, 38.5% and 58.3% 
respectively. Other drugs that have been used include 
tamoxifen, and as well as immunosuppressive drugs like 
cyclosporine and azathioprine [2]. A few studies showed 
some benefit with tamoxifen – in these studies the patients 
were receiving concomitant oral corticosteroids [7, 8, 9]. Data 
on immunosuppressive drugs other than corticosteroids are 
limited and therefore strong recommendations cannot be 
made on their efficacy. Our patient received approximately 
six weeks of  oral prednisone without any improvement.
The prognosis of  EPS is very poor once the patient 
develops symptoms, with a mortality rate of  more than 
60% within four months of  being diagnosed. Our patient 
died exactly one year after diagnosis due to malnutrition 
with overwhelming sepsis. The usual causes of  death are 
malnutrition with sepsis, or following surgery [2]. Preventive 
measures should be instituted in all patients commenced 
on CAPD. These include avoiding hypertonic dialysate 
solutions and preservation of  residual renal function [2, 4]. 
Electively stopping CAPD after eight years and switching to 
haemodialysis is another consideration [2].
conclusion
EPS is a rare but devastating complication of  CAPD. It 
classically presents insidiously with clinico-radiographic 
features of  bowel obstruction. Haemorrhagic ascites 
following transfer from peritoneal dialysis to haemodialysis 
may be the initial form of  presentation. Clinicians should 
have a high index of  suspicion for EPS in any patient on 
peritoneal dialysis with non-specific abdominal symptoms. 
Preventive strategies should be instituted in all patients 
commenced on CAPD as the response to treatment is poor. 
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figure 1, panel a: abdominal X-ray showing bowel 
obstruction.
figure 1, panel b: computed tomography of  the 
abdomen showing loculated ascites anteriorly with 
tethering of  bowel to the posterior abdominal wall and 
dilated loops of  bowel.
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